Zobrazeno 1 - 10
of 75
pro vyhledávání: '"Saurabh P Nagar"'
Autor:
Jae Cheol Lee, Jen-Yu Hung, Young-Chul Kim, Gee-Chen Chang, Seung Soo Yoo, Sheng-Hsiung Yang, Keith L Davis, Saurabh P Nagar, Aliki Taylor, Sung Yong Lee, Jin-Yuan Shih
Publikováno v:
Asian Pacific Journal of Cancer Biology, Vol 6, Iss 2, Pp 123-132 (2021)
Introduction: The preferred first-line (1L) treatment for epidermal growth factor receptor (EGFR) mutation-positive (EGFRm) advanced/metastatic non-small lung cancer (NSCLC) are EGFR-tyrosine kinase inhibitors (TKIs). However, most patients treated w
Externí odkaz:
https://doaj.org/article/f6923fbd9dbe48b0aa006b9839c05b16
Publikováno v:
Cancer Medicine, Vol 10, Iss 8, Pp 2690-2702 (2021)
Abstract Background Information on overall survival (OS) and adverse events (AEs) in patients with chronic lymphocytic leukemia (CLL) is mostly available from clinical trials. We therefore conducted a population‐based retrospective cohort study to
Externí odkaz:
https://doaj.org/article/ee10a73acaf446daa5e76ae59e569ae3
Publikováno v:
Cancer Medicine, Vol 8, Iss 8, Pp 3803-3810 (2019)
Abstract Introduction Contemporary data describing treatment patterns, adverse events (AEs), and outcomes in patients with chronic lymphocytic leukemia (CLL) in clinical practice are lacking. We conducted a retrospective cohort study and assessed tre
Externí odkaz:
https://doaj.org/article/8f0d4103cfdf4d6096dda24a3ec502d5
Autor:
Huamao Mark Lin, Keith L. Davis, James A. Kaye, Katarina Luptakova, Saurabh P. Nagar, Mohamad Mohty
Publikováno v:
Advances in Hematology, Vol 2019 (2019)
Background. Limited data are available from real-world practices in Europe describing prevailing treatment patterns and outcomes in relapsed/refractory multiple myeloma (RRMM), particularly by cytogenetic risk. Methods. A retrospective medical record
Externí odkaz:
https://doaj.org/article/d1602ce2e4904f4dab213fe183f4e6f9
Autor:
J. Roeper, Keith L. Davis, Saurabh P Nagar, W. Sawyer, Nicolas Girard, Aliki Taylor, Ning Yu, Parisa Karimi, Frank Griesinger, Josephine Feliciano, Riyaz Shah
Publikováno v:
Drugs-Real World Outcomes
Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred first-line (1L) therapy for EGFR mutation-positive (EGFRm) advanced/metastatic non-small cell lung cancer (NSCLC). Objective Our objective was to d
Autor:
Serge A. Jabbour, Lisa I. Glasser, Brandon J. Patterson, Saurabh P. Nagar, Juliana L. Meyers, Jean-Etienne Poirrier
Objective Data on real-world burden of herpes zoster (HZ) in adults with type 2 diabetes mellitus (T2D) in the U.S. are limited. We assessed HZ in patients with and without T2D and measured the impact of HZ on healthcare resource use (HCRU) and costs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c469ef0d5bd37c5c66d1a1d15288f05
https://doi.org/10.2337/figshare.20736703
https://doi.org/10.2337/figshare.20736703
Autor:
Saurabh P. Nagar, Daniel S. Mytelka, Sean D. Candrilli, Yulia D’yachkova, Maria Lorenzo, Bernd Kasper, Jose Antonio Lopez-Martin, James A. Kaye
Publikováno v:
Sarcoma, Vol 2018 (2018)
Objective. To describe real-world treatment patterns and outcomes for patients with advanced soft tissue sarcoma (STS) not amenable to surgery or radiotherapy in the United Kingdom, Spain, Germany, and France. Methods. Physicians completed a web-base
Externí odkaz:
https://doaj.org/article/3a3db765c7364d779e85984436710234
Autor:
Daniel S. Mytelka, Saurabh P. Nagar, Yulia D’yachkova, Elizabeth M. La, James A. Kaye, Sean D. Candrilli, Bernd Kasper, Jose Antonio Lopez-Martin, Maria Lorenzo
Publikováno v:
Sarcoma, Vol 2018 (2018)
Objective. To describe health care resource utilization and costs for patients with advanced soft tissue sarcoma (STS) in the United Kingdom (UK), Spain, Germany, and France. Methods. Physicians abstracted data for adult patients with a diagnosis of
Externí odkaz:
https://doaj.org/article/05c135348ffc4269ad5231c6254d7b9d
Publikováno v:
Future Oncology. 17:2759-2768
Aim: This study evaluated the effectiveness of lenvatinib monotherapy for first-line treatment of unresectable hepatocellular carcinoma (uHCC) in a real-world setting. Materials & methods: This retrospective cohort study included patients who initiat
Publikováno v:
Cancer reports (Hoboken, N.J.)REFERENCES.
Lenvatinib monotherapy was approved in the United States for first-line treatment of patients with unresectable hepatocellular carcinoma (uHCC) in 2018. This study assessed real-world treatment patterns and outcomes of lenvatinib beyond first-line sy